Latest news with #MDxHealthSA
Yahoo
15-05-2025
- Business
- Yahoo
MDxHealth SA (MDXH) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Operational ...
Revenue Growth: 22% increase to $24.3 million for Q1 2025 compared to $19.8 million in Q1 2024. Gross Profit: $15.5 million, a 29% increase from $12.1 million in Q1 2024. Gross Margin: 63.8%, up from 60.8% in Q1 2024. Operating Loss: Decreased 31% to $4.6 million from $6.6 million in Q1 2024. Net Loss: Increased 8% to $9.2 million, primarily due to non-cash fair value adjustments. Adjusted EBITDA: Negative $1.3 million, a 71% improvement from negative $4.5 million in Q1 2024. Cash and Cash Equivalents: $65.7 million as of March 31, 2025, with a pro forma balance of $37.7 million after a $28 million earnout payment. Tissue-Based Test Volume: 41% increase to approximately 12,600 tests. Liquid-Based Test Volume: 9% increase to almost 12,000 tests. Total Billable Volume: Approximately 24,000 tests, a 24% increase. Warning! GuruFocus has detected 5 Warning Signs with MDXH. Release Date: May 14, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. MDxHealth SA (NASDAQ:MDXH) achieved a 22% revenue growth in Q1 2025, marking the 16th consecutive quarter of 20% or greater revenue growth. The company reported a significant increase in tissue-based test volumes, with a 41% growth over the prior year period. Gross profit for the quarter increased by 29%, with gross margins improving to 63.8% from 60.8% in Q1 2024. MDxHealth SA (NASDAQ:MDXH) has not expanded its sales organization, yet continues to achieve growth, indicating strong leverage from its existing sales channels. The company is on track to achieve positive adjusted EBITDA in Q2 2025, reflecting strong financial management and operational efficiency. Net loss increased by 8% to $9.2 million, primarily due to non-cash fair value adjustments. Operating expenses grew by 8%, driven by increased clinical studies, stock-based compensation, and scale. The liquid-based test segment showed a lower growth rate of 9% compared to the tissue-based segment. Cash and cash equivalents were reduced to $37.7 million after a $28 million earnout payment to Exact Sciences. The company faces inherent risks and uncertainties, as highlighted in their forward-looking statements and SEC filings. Q: What factors are driving the growth in the tissue-based segment of MDxHealth's menu? A: Michael McGarrity, CEO, explained that the diagnostic value of their ConfirmMDx test is increasingly appreciated by urology customers. The test addresses limitations of needle biopsies by interrogating each core of the biopsy, offering a 96% negative predictive value. This helps avoid unnecessary repeat biopsies and detects missed cancers, providing significant value from both healthcare economics and patient care perspectives. Q: How is MDxHealth gaining market share with the GPS test? A: Michael McGarrity, CEO, stated that the company is converting the market and taking competitive share by leveraging their strong sales channel and the unique features of the GPS test. The test requires significantly less tumor tissue than competitors, offering a higher valid result rate, which is compelling to urologists and pathologists. Q: What impact did weather and fewer sales days have on MDxHealth's Q1 performance? A: Michael McGarrity, CEO, noted that while weather and fewer sales days can impact performance, the company did not see these factors significantly affecting their Q1 results. They expect continued execution and growth in Q2 without providing specific guidance. Q: How is MDxHealth approaching potential M&A opportunities? A: Michael McGarrity, CEO, mentioned that while they are open to growth opportunities, they are disciplined in their approach. They are considering both transformative M&A and channel growth opportunities, ensuring any potential acquisition is de-risked, particularly in terms of regulatory and reimbursement dynamics. Q: What is the outlook for MDxHealth's operating expenses and revenue growth? A: Ron Kalfus, CFO, stated that operating expenses are expected to remain flat, with revenue growth driving improved adjusted EBITDA. The company is confident in sustaining 20% revenue growth, with much of the growth in revenue dollars expected to drop through to EBITDA dollars. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
14-05-2025
- Business
- Yahoo
MDxHealth SA (MDXH) Reports Q1 Loss, Tops Revenue Estimates
MDxHealth SA (MDXH) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.31 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -46.15%. A quarter ago, it was expected that this company would post a loss of $0.20 per share when it actually produced a loss of $0.14, delivering a surprise of 30%. Over the last four quarters, the company has surpassed consensus EPS estimates just once. MDxHealth SA , which belongs to the Zacks Medical Info Systems industry, posted revenues of $24.29 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 0.76%. This compares to year-ago revenues of $19.83 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. MDxHealth SA shares have lost about 24.9% since the beginning of the year versus the S&P 500's gain of 0.1%. While MDxHealth SA has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for MDxHealth SA: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.11 on $26.44 million in revenues for the coming quarter and -$0.40 on $108.55 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical Info Systems is currently in the top 20% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the same industry, P3 Health Partners Inc. (PIII), is yet to report results for the quarter ended March 2025. The results are expected to be released on May 15. This company is expected to post quarterly loss of $5 per share in its upcoming report, which represents a year-over-year change of +37.5%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. P3 Health Partners Inc.'s revenues are expected to be $363.75 million, down 6.4% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report MDxHealth SA (MDXH) : Free Stock Analysis Report P3 Health Partners Inc. (PIII) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
30-04-2025
- Business
- Yahoo
Mdxhealth to Release First Quarter 2025 Financial Results on May 14
IRVINE, California – April 30, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH), a leading precision diagnostics company, today announced it will release its financial results for the first quarter ended March 31, 2025, after market close on Wednesday, May 14, 2025. Title: Mdxhealth Presents First Quarter 2025 Financial Results andCorporate Update Conference Call and Webcast Speakers: Michael K. McGarrity, Chief Executive OfficerRon Kalfus, Chief Financial Officer Date: May 14, 2025 Time: 4:30pm ET/ 22:30 CET Conference Call Dial-in Details: United States: 1-844-825-9789Belgium: 0800 38 961The Netherlands: 0800 94 94 506United Kingdom: 0808 238 9064 Conference ID: 10199102 Webcast: The webcast should be accessed 15 minutes prior to the conference call start time. A replay of the webcast will be available following the conclusion of the live call and will be accessible on the Company's website. About Mdxhealth Mdxhealth is a leading precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatment. The Company's tests are based on proprietary genomic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis and prognosis of urologic cancers and other urologic diseases. The Company's U.S. headquarters and laboratory operations are in Irvine, California, with additional laboratory operations in Plano, Texas. European headquarters are in Herstal, Belgium. For more information, visit and follow us on social media at: and MDxHealth info@ LifeSci Advisors (IR & PR)US: +1 949 271 9223ir@ Sign in to access your portfolio
